חובות לטווח קצר של החברה: Bio-Path Holdings, Inc. (BPTH)

Bio-Path Holdings (BPTH) is developing a unique RNA therapy environment to combat oncohematology, utilizing the DNAbilize system to secure clinics through proprietary treatment methods. Serving as the primary valuation tool, this chart on GURU.Markets confirms the asset's dynamics, where the indicator stands at 0.00. Bio-Path Holdings (BPTH) is implementing liposomal microengineering for targeted leukemia treatment, although it currently relies on cash reserves and new share issuances to fund its research.

A comparative liquidity analysis requires an assessment of liabilities with maturities of up to one year, which measure a company's ability to service current loans without raising emergency capital. For Bio-Path Holdings (BPTH), which invests in the development of DNAbilize antitumor drugs, the short-term debt trend reflects the balance between the availability of borrowed R&D financing and the risk of reduced banking limits.